<DOC>
	<DOCNO>NCT01103310</DOCNO>
	<brief_summary>Visual assessment diagnostic PET/CT ( positron emission tomography/computed tomography ) image obtain single intravenous injection BAY94-9392 patient cancer inflammation .</brief_summary>
	<brief_title>Radiation Dosimetry , Metabolism , Pharmacokinetics , Safety Tolerability PET Imaging With BAY94-9392 Healthy Volunteers Patients With Cancer Inflammation</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<criteria>Inclusion criterion : In Germany Healthy volunteer Males/females ≥ 50 ≤ 65 year Patients Males/females ≥ 35 ≤ 75 year histologically confirm diagnosis non small cell lung cancer adenocarcinoma breast positive FDGPET patient primary prostate cancer schedule prostatectomy patient prostate tumor recurrence positive cholinePET , initial disease histologically confirm inflammation positive FDGPET In Korea Patients Males/females ≥ 35 ≤ 75 year histologically confirm diagnosis non small cell lung cancer , adenocarcinoma breast hepatocellular cancer positive FDGPET patient primary prostate cancer schedule prostatectomy patient prostate tumor recurrence positive cholinePET , initial disease histologically confirm inflammation ( positive FDGPET mandatory , could also do screen examination ) Exclusion criterion : Concurrent severe and/or uncontrolled and/or unstable medical disease cancer inflammation ( e.g . poorly control diabetes , congestive heart failure , myocardial infarction within 12 month prior plan injection BAY 949392 , unstable uncontrolled hypertension , chronic renal hepatic disease , severe pulmonary disease ) could compromise participation study Known sensitivity study drug component preparation</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Neoplasm</keyword>
	<keyword>PET/CT diagnosis</keyword>
	<keyword>PET tracer</keyword>
</DOC>